| Literature DB >> 35542000 |
Shabir H Lone1, Salman Jameel2, Muzzaffar A Bhat3, Rayees A Lone2, Ray J Butcher4, Khursheed A Bhat2.
Abstract
An unusual quinazoline alkaloid (1) was obtained when 2-aminobenzaldehyde was refluxed with pyrrolidine in ethanol for 12 h. The synthesized compound was characterized using spectral data analysis augmented with X-ray and literature precedent. Single crystal analysis depicted four conformations differing slightly in bond angles and bond lengths. Compound 1 crystallizes in a triclinic crystal system with a P1̄ space group having two molecules within the unit cell. The experimentally obtained parameters were compared to those obtained theoretically, which depicted a good agreement. Using the DFT/B3LYP/6-31G (d,p) level of theory, HOMO-LUMO energy gap, molecular electrostatic potential (MEP), vibrational (IR) and NMR analyses were carried out. The HOMO-LUMO energy gap allowed the calculation of chemical hardness, chemical inertness, electronegativity and the electrophilicity index of the molecule, which depicted its potential kinetic stability and reactivity. Prediction of activity spectra of the target compound revealed that compound 1 possesses notable antineoplastic activity with P a = 0.884. The molecule was therefore evaluated against various cancerous cell lines in an in vitro SRB assay which depicted that compound 1 possesses the highest growth inhibition activity against THP-1 cell lines with an IC50 of 7 μM. This journal is © The Royal Society of Chemistry.Entities:
Year: 2018 PMID: 35542000 PMCID: PMC9082197 DOI: 10.1039/c8ra00138c
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Synthesis of an unusual quinazoline alkaloid (1).
Fig. 2Mechanism involved in the formation of quinazoline (1).
Fig. 3Four different conformations (a–d) of compound 1 as shown by single crystal X-ray analysis.
Crystal data and structure refinement of compound 1
| Identification code | Shelx |
| Empirical formula | C101H97Cl3N16 |
| Formula weight | 1641.29 |
| Temperature | 153 (2) K |
| Wavelength | 1.54184 Å |
| Crystal system | Triclinic |
| Space group |
|
| Unit cell dimensions |
|
|
| |
|
| |
| Volume | 4093.1 (2) Å3 |
|
| 2 |
| Density (calculated) | 1.332 mg m−3 |
| Absorption coefficient | 1.497 mm−1 |
|
| 1732 |
| Crystal size | 0.345 × 0.275 × 0.233 mm3 |
| Theta range for data collection | 3.492 to 76.684° |
| Index ranges | −16 ≤ |
| Reflections collected | 29 828 |
| Independent reflections | 16 636 [ |
| Completeness to theta = 67.684° | 99.8% |
| Absorption correction | Gaussian |
| Max. and min. transmission | 1.000 and 0.322 |
| Refinement method | Full-matrix least-squares on |
| Data/restraints/parameters | 16 636/12/1111 |
| Goodness-of-fit on | 1.045 |
Comparative analysis of experimentally obtained bond lengths of four conformers with that obtained theoretically (notable ones have been shown, for all refer to ESI file)
| Bond | Exp. bond length (Å) of Conf. A | Exp. bond length (Å) of Conf. B | Exp. bond length (Å) of Conf. C | Exp. bond length (Å) of Conf. D | Theo. bond length (Å) |
|---|---|---|---|---|---|
| N(4)–H(4) | 0.80 | 0.88 | 0.86 | 0.96 | 1.0138 |
| C(2)–C(3) | 1.496 | 1.531 | 1.527 | 1.566 | 1.5385 |
| C(3)–C(4) | 1.518 | 1.520 | 1.523 | 1.485 | 1.5335 |
| C(6)–C(7) | 1.399 | 1.383 | 1.511 | 1.512 | 1.420 |
| C(11)–C(12) | 1.525 | 1.514 | 1.399 | 1.399 | 1.487 |
| C(21)–C(22) | 1.388 | 1.385 | 1.377 | 1.386 | 1.398 |
Fig. 4A perspective view of the crystal packing in the compound 1.
Hydrogen bonds for compound 1 [Å and °]
| D–H⋯A |
|
|
| ∠(DHA) |
|---|---|---|---|---|
| N(4B)–H(4B)⋯N(3A) | 0.88(5) | 2.34(5) | 3.143(4) | 153(4) |
| N(4D)–H(4D)⋯N(3C) | 0.96(6) | 2.25(6) | 3.125(4) | 151(4) |
| C(5D)–H(5DA)⋯Cl(1T) | 1.00 | 2.96 | 3.718(7) | 133.1 |
Calculated energy values for compound 1 using B3LYP/6-31G (d,p) level of theory
| Parameter | Compound 1 |
|---|---|
| Energy (au) | −1186.014 |
| Dipole moment (debye) | 3.499 |
|
| −0.139 |
|
| −0.045 |
|
| 0.094 |
|
| −0.175 |
|
| −0.005 |
|
| 0.169 |
| Hardness ( | 0.047 |
| Chemical potential ( | 0.092 |
| Electronegativity ( | −0.092 |
| Electrophilicity index ( | 0.012 |
Comparsion of theoretical and experimental NMR data of compound 1
| 1H NMR | 13C NMR | ||
|---|---|---|---|
| Experimental ( | Theoretical | Experimental ( | Theoretical |
| 7.30–6.70 (m, 12H) | 8.10 (s, 1H) | 146.08 | 133.86 |
| 5.96 (s, 1H) | 7.60 (s, 1H) | 144.23 | 132.90 |
| 5.28 (d, | 7.38 (s, 2H) | 140.08 | 118.62 |
| 4.82 (br s, 1H) | 7.19 (s, 2H) | 130.20 | 114.61 |
| 4.52 (s, 1H) | 7.10 (s, 2H) | 129.59 | 113.18 |
| 3.32 (m, 2H) | 6.98 (s, 1H) | 129.12 | 112.86 |
| 2.85 (m, 2H) | 6.78 (s, 1H) | 128.73 | 112.63 |
| 2.05–1.92 (m 4H) | 6.72 (s, 1H) | 128.48 | 111.98 |
| 6.65 (s, 1H) | 128.31 | 110.86 | |
| 6.59 (s, 1H) | 127.88 | 110.58 | |
| 6.17 (s, 1H) | 124.97 | 109.86 | |
| 5.83 (s, 1H) | 124.74 | 108.72 | |
| 5.39 (s, 1H) | 124.56 | 108.11 | |
| 4.10 (s, 1H) | 123.93 | 107.89 | |
| 3.53 (s, 1H) | 123.32 | 106.40 | |
| 3.06 (s, 1H) | 123.09 | 105.42 | |
| 2.62 (s, 1H) | 119.98 | 104.73 | |
| 1.89 (s, 1H) | 117.44 | 97.81 | |
| 1.71 (s, 1H) | 84 | 94.84 | |
| 1.66 (s, 1H) | 71.04 | 88.20 | |
| 1.38 (s, 1H) | 64.12 | 76.45 | |
| 51.43 | 45.55 | ||
| 51.43 | 36.62 | ||
| 23.76 | 19.07 | ||
| 23.76 | 18.70 | ||
Comparsion of theoretical and experimental IR (cm−1) data of compound 1 (selected modes only)
| Experimental (cm−1) | Theoretical (cm−1) | Experimental (cm−1) | Theoretical (cm−1) | Experimental (cm−1) | Theoretical (cm−1) |
|---|---|---|---|---|---|
| 3401 | 3224 | 1465 | 1472 | 960 | 967 |
| 3062 | 3061 | 1341 | 1336 | 856 | 857 |
| 2980 | 3028 | 1301 | 1314 | 795 | 792 |
| 2830 | 3006 | 1253 | 1257 | 750 | 753 |
| 2800 | 2986 | 1222 | 1225 | 685 | 689 |
| 1620 | 1613 | 1120 | 1126 | 620 | 617 |
| 1560 | 1555 | 1036 | 1031 | 580 | 577 |
| 1500 | 1501 | 1000 | 987 | 534 | 535 |
| 1490 | 1475 | 982 | 979 | 512 | 521 |
PASS prediction for the activity spectrum of compound 1 with Pa > 0.5
|
|
| Activity name |
|---|---|---|
| 0.884 | 0.003 | Antineoplastic enhancer |
| 0.851 | 0.009 | 5 Hydroxytryptamine release stimulant |
| 0.769 | 0.014 | Nicotinic alpha-2-beta-2-receptor antagonist |
| 0.728 | 0.026 | Nicotinic alpha-6-beta-3-beta-4-alpha-5-receptor antagonist |
| 0.707 | 0.007 | Antihypoxic |
| 0.676 | 0.014 | Thioredoxin inhibitor |
| 0.690 | 0.080 | Phobic disorders treatment |
| 0.605 | 0.003 | Poly(ADP-ribose) polymerase inhibitor |
| 0.637 | 0.052 | Fibrinolytic |
| 0.591 | 0.009 | Atherosclerosis treatment |
| 0.585 | 0.007 | Stroke treatment |
| 0.576 | 0.010 | Octopamine antagonist |
| 0.617 | 0.065 | Antineurotic |
| 0.576 | 0.027 | ( |
| 0.567 | 0.021 | ( |
| 0.559 | 0.030 | 1,4-Lactonase inhibitor |
| 0.563 | 0.034 | Chloride peroxidase inhibitor |
| 0.579 | 0.054 | Pseudolysin inhibitor |
| 0.589 | 0.068 | Glycosylphosphatidylinositol phospholipase D inhibitor |
| 0.550 | 0.033 | Alopecia treatment |
| 0.594 | 0.089 | Antieczematic |
| 0.580 | 0.098 | Testosterone 17 beta-dehydrogenase (NADP+) inhibitor |
| 0.503 | 0.077 | Calcium channel (voltage-sensitive) activator |
| 0.528 | 0.114 | Nootropic |
| 0.516 | 0.065 | Phthalate 4,5-dioxygenase inhibitor |
| 0.526 | 0.081 | Kidney function stimulant |